Evaluation agreement with Hemakim regarding potential distribution in Turkey extended to the end of 2020

Hemcheck Sweden AB has extended the evaluation agreement with Hemakim Tibbi Ürünler San.Ve Tic. A.S (”Hemakim”) to the end of 2020. The evaluation agreement that is now extended was formed to evaluate the collaboration and market opportunity. After the extended evaluation period, the agreement can be extended into a distribution agreement with the same terms as earlier communicated.

-Both parties are in full agreement to continue and complete the evaluation that has been started but is delayed by the current pandemic. We remain very positive and see potential for a long-term collaboration with Hemakim, says Joen Averstad, CEO of Hemcheck. 

For further information contact:

Hemcheck Sweden AB (publ)

Joen Averstad, CEO

Tel: +46 76 108 8191

Email: joen.averstad@hemcheck.com

About Hemakim

Hemakim is a family-owned Turkish company group founded in 1983. The Group consists of several legal entities focusing on a wide number of fields such as in-vivo and in-vitro diagnostics in hospitals, immunohematology, microbiology, etc. Hemakim has its head office in Istanbul and has several regional offices and sub-dealers throughout Turkey. The group turnover is ca 50 MUSD. Hemakim is a partner to several large companies such as Thermo Scientific. 

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly services for the detection of hemolysed blood samples in direct connection with blood sampling. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is based in Karlstad and is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB, 08-528 00 399, info@fnca, is the Certified Adviser to the company.